Does the Aid of MelaFind Affect Clinical Management Decisions

Completed

Conditions studied: Melanoma

In brief

The objective of this study is to determine and compare the performance of dermatologists (in Germany) on the excision decision against the performance of MelaFind, a non-invasive and objective multi-spectral computer vision system designed as a tool to aid dermatologists in the detection of early melanoma. The hypothesis is that MelaFind's sensitivity is superior to the average excisions sensitivity of dermatologists. Another objective is to determine and compare the performance of dermatologists (in Germany) with and without the aid of MelaFind. The hypothesis is that the average excision sensitivity of dermatologists with the aid of MelaFind is superior to the average excision sensitivity of dermatologists without the aid of MelaFind. A similar study was previously conducted with dermatologists in the US (NCT01011153). An exploratory objective is to compare the excision decisions of dermatologists from the previous study (in the US) to dermatologists in in this study (in Germany).

Key facts

Study ID

NCT01387581

Run by

MELA Sciences, Inc.

People needed

227

Starts

2011-10-01

Expected to finish

2012-03-01

Last updated by the study team

2014-11-14

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Only board certified dermatologists

You may not qualify if…

• May not have previously participated in MELA Protocols 20061, 20081 or 20063

Where it is running

• MELA Sciences — Irvington, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.